Head-To-Head Analysis: Edgewise Therapeutics (NASDAQ:EWTX) versus ABVC BioPharma (NASDAQ:ABVC)

Edgewise Therapeutics (NASDAQ:EWTX) and ABVC BioPharma (NASDAQ:ABVC) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Insider & Institutional Ownership

11.4% of ABVC BioPharma shares are owned by institutional investors. 23.2% of Edgewise Therapeutics shares are owned by insiders. Comparatively, 19.0% of ABVC BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Edgewise Therapeutics and ABVC BioPharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-31.97%	-30.46%
ABVC BioPharma	N/A	-65.11%	-40.13%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Edgewise Therapeutics and ABVC BioPharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1	1	6	2	2.90
ABVC BioPharma	1	0	0	0	1.00

Edgewise Therapeutics presently has a consensus price target of $38.44, suggesting a potential upside of 21.74%. Given Edgewise Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Edgewise Therapeutics is more favorable than ABVC BioPharma.

Earnings & Valuation

This table compares Edgewise Therapeutics and ABVC BioPharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79 million	($1.63)	-19.37
ABVC BioPharma	$510,000.00	53.37	-$7.91 million	($0.40)	-2.68

ABVC BioPharma has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Edgewise Therapeutics has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500. Comparatively, ABVC BioPharma has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500.

Summary

Edgewise Therapeutics beats ABVC BioPharma on 7 of the 13 factors compared between the two stocks.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

About ABVC BioPharma

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.